(TheNewswire) VANCOUVER, British Columbia - TheNewswire – April 23 ,2023 - Astron Connect Inc. (TSXV:AST) (“Astron” or the “Company”) announces the resignation of (Lewis) Hai Xing, who has...
(TheNewswire) VANCOUVER, BC – TheNewswire - February 28, 2023 – Astron Connect Inc. (the “Company” or “Astron”) (TSXV:AST) today announced its first quarter results for the thre...
(TheNewswire) Vancouver, B C - TheNewswire - January 30, 2023 - Astron Connect Inc. (the “ Company ” or “ Astron ”) (TSXV:AST) today announced its full year results for the fisc...
Top-line data at month 12 in a Phase 1/2a clinical trial, SCiStar , evaluating Asterias Biotherapeutics' (NYSEMKT: AST ) OPC1 cells in patients with severe spinal cord injuries showed a sustained effect. More news on: Asterias Biotherapeutics, Inc., Healthcare stocks news, Stocks on the m...
FREMONT, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today ...